Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
Refine your Search
| Title |
Publication Date |
Price |
Relevance |
Moxifloxacin
Pipeline Developer
|
Ongoing |
£3795 |
100 % |
Moxifloxacin: Extended Country Coverage
Pipeline Selector
|
Ongoing |
£610 |
96 % |
Moxifloxacin: Core Country Coverage
Pipeline Selector
|
Ongoing |
£260 |
96 % |
Shionogi: Pipeline - Products - Performance - Potential
|
March 2008 |
£595 |
50 % |
Schering-Plough
Pipeline ,Products ,Performance ,Potential
|
August 2008 |
£595 |
35 % |
Bayer
Pipeline, Products ,Performance ,Potential
|
September 2008 |
£595 |
33.95 % |
Dr Reddy's Laboratories Generics Company Intelligence Report
|
June 2008 |
£195 |
19.6 % |
Dr Reddy's Laboratories Generics Company Intelligence Report
|
June 2008 |
£195 |
19.6 % |
Stakeholder Opinions: Tuberculosis - Development pipeline shows signs of life
Healthcare
|
March 2009 |
£2000 |
19.25 % |
Stakeholder Opinions: Skin and soft tissue infections
|
July 2009 |
£3800 |
15.4 % |
Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics
2009-2023
|
January 2009 |
£1499 |
14.7 % |
Bayer Schering Pharma AG: PharmaVitae Profile
|
July 2009 |
£5700 |
14.7 % |
Pipeline Insight: Depression
Novel drugs to grow third-line market
|
March 2007 |
£6000 |
14.7 % |
Bayer Schering Pharma Ag
PharmaVitae Profile
|
July 2008 |
£3010 |
14.35 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
9.45 % |
Generic Competition, 2007–11
The impact of patent expiries on sales of major drugs
|
February 2007 |
£1375 |
9.1 % |
Stakeholder Insight: Respiratory Tract Infections in the USA
The demise of narrow-spectrum antibiotics
|
November 2006 |
£8000 |
8.4 % |
Stakeholder Insight: Respiratory Tract Infections in the USA
The demise of narrow-spectrum antibiotics
|
November 2006 |
£8000 |
8.4 % |
World Generic Market Report 2009
|
January 2009 |
£595 |
3.15 % |
